PSA screening: the most controversial test in preventive medicine

No screening test in medicine generates more debate than the prostate-specific antigen (PSA) test. Advocates say it saves lives by detecting prostate cancer early. Critics say it leads to overdiagnosis and overtreatment of cancers that would never have caused harm. Both are right — and that's exactly the problem.

The evidence: a mixed picture

The two landmark PSA screening trials reached seemingly opposite conclusions. The European ERSPC trial (n=182,000) showed a 20% reduction in prostate cancer mortality after 16 years of follow-up. The US PLCO trial (n=76,685) showed no benefit.

The difference? The PLCO trial was contaminated — a large proportion of men in the "control" group had already been screened with PSA before the trial began, or got screened during the trial outside the protocol. It wasn't really comparing screened vs. unscreened — it was comparing "screened" vs. "also screened." When statisticians corrected for this contamination, the PLCO data actually aligned with the ERSPC findings.

So PSA screening works — in the sense that it detects prostate cancer earlier, and earlier detection reduces mortality. The problem is what else it detects.

The overdiagnosis problem

Prostate cancer is remarkably common. Autopsy studies show that about 50% of men over 70 have prostate cancer cells in their prostate — but most of these cancers are low-grade, slow-growing, and would never have caused symptoms or death. They are "cancers" only in the pathological sense.

PSA screening can't distinguish between aggressive cancers that will kill you and indolent ones that won't. An elevated PSA triggers a biopsy, a biopsy finds cancer, and the word "cancer" triggers treatment — often surgery or radiation — with significant side effects including incontinence and erectile dysfunction.

For every man whose life is saved by PSA screening, an estimated 3–4 men are treated for cancers that would never have caused them harm. That's a difficult trade-off, and it's why the USPSTF rates PSA screening as Grade C for men 55–69 (individual decision) and Grade D for men under 55 or over 70.

Who benefits most from PSA screening

The risk-benefit calculation shifts significantly based on individual risk factors:

• Men with family history of prostate cancer (especially first-degree relative diagnosed before 65): higher benefit, start discussion at 40–45
• Men of African descent: approximately 2x higher incidence and more aggressive biology; earlier screening discussion warranted
• BRCA2 carriers: significantly elevated prostate cancer risk; annual screening from 40
• Men over 70 with limited life expectancy: screening is unlikely to benefit and likely to cause harm

How we handle it at Health Detectors

Our approach to PSA follows the evidence precisely. For men ≥45 or those with family history or other risk factors, the Quarterback Physician initiates the shared decision-making conversation during the Day 1 consultation — with enough time to actually have it properly.

If PSA is elevated, the next step is not automatic biopsy. It's multiparametric MRI (mpMRI) — a non-invasive imaging study that can identify clinically significant cancers with high accuracy. If the MRI shows a PI-RADS ≥3 lesion, targeted biopsy is recommended. If MRI is normal, active surveillance with repeat PSA is usually appropriate.

This MRI-first approach dramatically reduces unnecessary biopsies — and it's increasingly recognized as the standard of care in European urology (EAU Guidelines 2024).